Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 24;15(1):26881.
doi: 10.1038/s41598-025-12725-w.

Therapeutic resistance and combination therapy for cancer: recent developments and future directions

Chendil Damodaran  1 , Je-Yoel Cho  2 , Cenap Güngör  3
Affiliations
Editorial

Therapeutic resistance and combination therapy for cancer: recent developments and future directions

Chendil Damodaran et al. Sci Rep. .

Abstract

The diverse and heterogeneous nature of cancer is a fundamental characteristic that is responsible for therapy resistance, progression, and recurrence of disease. In order to enhance therapeutic efficacy, novel combination therapies are currently being proposed and utilized in clinical practice to effectively manage or retard disease progression. Several factors contribute to therapeutic resistance, including elevated expression of survival factors, mutations in genes that limit therapeutic effectiveness, multidrug resistance, and the potential involvement of cancer stem cells. This Scientific Reports Collection covers the underlying mechanisms responsible for therapeutic resistance. Additionally, the publications from this Collection highlight numerous innovative molecules to overcome this resistance and significantly sensitize tumors across various cancer models.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. DeVita, V. T. Jr. & Chu, E. A history of cancer chemotherapy. Cancer Res.68, 8643–8653. 10.1158/0008-5472.CAN-07-6611 (2008). - PubMed
    1. Cohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res.8, 935–942 (2002). - PubMed
    1. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol.13, 239–246. 10.1016/S1470-2045(11)70393-X (2012). - PubMed
    1. Park, K. et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol.17, 577–589. 10.1016/S1470-2045(16)30033-X (2016). - PubMed
    1. Fan, W., Chang, J. & Fu, P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med. Chem.7, 1511–1519. 10.4155/fmc.15.93 (2015). - PMC - PubMed

Publication types

LinkOut - more resources